United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
United Therapeutics Corp. (UTHR) PT Raised to $124 at Ladenburg Thalmann
February 28, 2019 8:41 AM ESTLadenburg Thalmann analyst Matthew Kaplan raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $124.00 (from $117.00) while maintaining a Neutral rating.
... MoreUnited Therapeutics (UTHR) Tops Q4 EPS by 79c, Revenues Beat
February 27, 2019 6:03 AM ESTUnited Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $3.34, $0.79 better than the analyst estimate of $2.55. Revenue for the quarter came in at $381.4 million versus the consensus estimate of $355.83 million.
"2018 was a truly transformative year for United Therapeutics. We signed four major agreements to acquire new product... More
